Advanced search    

Search: authors:"Atul Deodhar"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

Introduction ‘REASSURE’ (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors). Methods A total of 637 patients were randomized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and...

The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis

, USA 2 Atul Deodhar Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms

Unanswered questions in the management of axial spondyloarthritis: an opinion piece

Xenofon Baraliakos 0 Atul Deodhar deodhara@ohsu.edu 0 0 X. Baraliakos Rheumazentrum Ruhrgebiet, Ruhr-University Bochum , Herne, Germany 1 ) Division of Arthritis and Rheumatic Diseases, Oregon Health

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study

Background In the present study, we evaluated relationships between serum biomarkers and clinical/magnetic resonance imaging (MRI) findings in golimumab-treated patients with ankylosing spondylitis. Methods In the GO-RAISE study, 356 patients with ankylosing spondylitis randomly received either placebo (n = 78) or golimumab 50 mg or 100 mg (n = 278) injections every 4 weeks...

IL-17 Inhibition in Axial Spondyloarthritis

Jackson Park Rd, Portland, OR 97239 , USA Abhijeet Danve is a rheumatology research fellow. Atul Deodhar is a professor of medicine. Final manuscript has been approved by all the authors, and they confirm ... Interest Abhijeet Danve declares that he has no conflict of interest. Atul Deodhar reports grants from Amgen, AbbVie, Janssen, Novartis, Pfizer, and UCB and personal fees from Amgen, AbbVie, Janssen

Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay

, Portland, OR , USA 2 Atul Deodhar 3 Division of Arthritis & Rheumatic Diseases (OP09), Oregon Health & Science University , 3181 SW Sam Jackson Park Road, Portland, OR 97239 , USA This study aimed to

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy

This study evaluated the efficacy and safety of adding etanercept to disease-modifying antirheumatic drugs (DMARDs) in patients with moderately active rheumatoid arthritis (RA). This randomized, double-blind, placebo-controlled study (ClinicalTrials.gov #NCT01313208) enrolled RA patients with Disease Activity Score using 28 joints with C-reactive protein (DAS28-CRP) >3.2 and ≤5.1...